View conference programme - The British Society for Rheumatology
View conference programme - The British Society for Rheumatology
View conference programme - The British Society for Rheumatology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
RCN<br />
<strong>The</strong> Royal College of Nursing (RCN) <strong>Rheumatology</strong> Forum Committee stand will have a number of useful guidance<br />
documents <strong>for</strong> practitioners as well as news on <strong>conference</strong>s and other educational initiatives <strong>for</strong> nurses. <strong>The</strong> RCN RF have<br />
recently published guidance <strong>for</strong> practitioners in the administration of subcutaneous methotrexate which will be available on<br />
the stand. Come and collect a copy or access it through the RCN website www.rcn.or.uk and go to guidelines.<br />
If you would like: • In<strong>for</strong>mation on joining the RCN<br />
• Wish to have advice on rheumatology nursing or how to develop rheumatology nursing posts<br />
• Would like to hear about bursaries and awards <strong>for</strong> nurses<br />
• Obtain guidelines prepared by the <strong>for</strong>um.<br />
• Or would like advice on nursing issues related to rheumatology<br />
Please come and visit our stand which will be manned by members of the committee who would be pleased to meet you<br />
<strong>The</strong> Scleroderma <strong>Society</strong><br />
<strong>The</strong> Scleroderma <strong>Society</strong> is a voluntary charity founded in 1982. Our aim is to help sufferers and their families to obtain<br />
appropriate support/in<strong>for</strong>mation and fund medical research. Scleroderma is a rare connective tissue disease and the <strong>Society</strong><br />
helps patients/members to feel less isolated through group meetings, quarterly newsletters, telephone and email helpline<br />
and message board on www.sclerodermasociety.co.uk. Patient in<strong>for</strong>mation leaflets available at our stand<br />
Surgicraft<br />
Surgicraft are delighted to be exhibiting Orthovisc, a pure hyaluronic acid injection indicated <strong>for</strong> the treatment of<br />
osteoarthritis in all synovial joints.<br />
Orthovisc is reported to have a significantly lower rate of adverse events, due to its proprietary manufacturing process and<br />
<strong>for</strong>mulation. As an efficient and safe 3-injection treatment, Orthovisc is fast becoming the HA of choice.<br />
Syner-Med<br />
Syner-Med (PP) Ltd supply Venofer ® (i.v. iron sucrose) to the UK and Ireland health care providers.<br />
Anaemia is a debilitating condition which can compound the symptoms of diseases such as rheumatoid arthritis. Venofer ® is<br />
suitable <strong>for</strong> the treatment of iron deficiency anaemia sometimes characterised in rheumatoid patients. Venofer ® does not<br />
contain Dextran, there<strong>for</strong>e worsening of the joint condition and anaphylaxis are not encountered. Venofer ® is also suitable<br />
<strong>for</strong> patients undergoing hip and knee surgery to support blood loss where blood transfusion avoidance is considered.<br />
TRB Chemedica<br />
TRB Chemedica specialises in the manufacture of a variety of highly purified, non-animal sourced, Hyaluronic Acid based<br />
products. Ostenil ® is <strong>for</strong> the relief of OA pain in large joints, <strong>for</strong> example the knee and hip & Ostenil mini ® is <strong>for</strong> the relief of<br />
OA pain in the small joints, <strong>for</strong> example, the upper and lower limbs and the facet joints of the lumbar spine.<br />
Vertec Scientific<br />
Vertec Scientific Ltd, the UK’s leading supplier of Dexa scanners introduces the Hologic DiscoveryTM including Hologic’s<br />
innovative Instant Vertebral Assessment (IVA), the new Standard of Vertebral Osteoporosis Assessment. Vertec are also<br />
launching the New Hologic ExplorerTM just released in the UK.<br />
Wisepress<br />
Wisepress Online Bookshop is pleased to present a display of titles selected especially <strong>for</strong> the <strong>British</strong> <strong>Society</strong> of<br />
<strong>Rheumatology</strong> Annual Conference 2004 from the world’s leading publishing houses. All titles can be bought / ordered at<br />
the congress or via our website: www.wisepress.co.uk . Whatever your book requirements, Wisepress will be happy to help<br />
Wyeth<br />
Enbrel is a twice – weekly injection licensed <strong>for</strong> the treatment of active rheumatoid arthritis (RA) including early RA,<br />
ankylosing spondylitis (AS), active and progressive psoratic arthritis (PsA) and active juvenile chronic arthritis (JCA). Enbrel<br />
has a unique mode of action as the only approved tumor necrosis factor (TNF) receptor, and has been used in over<br />
215,000 people worldwide, including over 4,000 <strong>British</strong> adults and children since its UK launch in 2000.<br />
88